Clinical relevance of cytomegalovirus viraemia

HIV Medicine

Volumn 12, Issue 7, 2011, Pages 394-402

  El Amari, E Boffi ^a   Combescure, C ^a   Yerly, S ^a   Calmy, A ^a   Kaiser, L ^a   Hasse, B ^b   Furrer, H ^c   Cavassini, M ^d   Vernazza, P ^e   Hirsch, Hh ^f   Bernasconi, E ^g   Hirschel, B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e St Gallen Hospital   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g Lugano Hospital   (Switzerland)

Author keywords

CMV DNA; CMV end organ disease; HIV; Mortality; Opportunistic diseases

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DEATH; DEMOGRAPHY; ESOPHAGUS CANDIDIASIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SWITZERLAND; VIRAL LOAD; VIREMIA;

EID: 79960022335     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00900.x     Document Type: Article

References (29)

1. Jacobson MA, Lurain NS, Hunt P. Cytomegalovirus viraemia in the modern antiretroviral era. HIV Med 2011; 12: 387-388.
2. Bowen EF, Sabin CA, Wilson P, Griffiths PD, Davey CC, Johnson MA. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997; 11: 889-893.
3. Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, Jones S. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 2005; 38: 538-544.
4. Baril L, Jouan M, Agher R et al. Impact of HAART on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 2000; 14: 2593-2596.
5. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of HAART. Clin Infect Dis 2000; 30: 231-233.
6. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999; 73: 7027-7030.
7. Spector SA, McKinely GF, Lalezari J P et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491-1497.
8. Grzywacz M, Deayton JR, Bowen EF et al. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3g/day or 6g/day in HIV-infected patients. J Med Virol 1999; 59: 323-328.
9. Casado JL, Arrizabalaga J, Montes M, Marti-Belda P, Tural C, Pinilla J. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS 1999; 13: 1497-1502.
10. Jabs DA, Holbrook JT, Van Natta ML et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005; 112: 771-779.
11. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 1999; 13: 1203-1206.
12. Wiselka MJ, Nicholson KG, Rowley S, Bibby K. Cytomegalovirus viraemia has poor predictive value for the development of cytomegalovirus disease in patients with advanced HIV-infection. J Infect 1999; 39: 187-192.
13. Edwards SG, Gover D, Scott C et al. Cytomegalovirus viral load testing of blood using quantitative polymerase chain reaction in acutely unwell HIV-1-positive patients lacks diagnostic utility. Int J STD AIDS 2007; 18: 321-323.
14. Yerly S, Perrin L, Van Delden C et al. Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J Clin Virol 2007; 38: 298-303.
15. Hadaya K, Wunderli W, Deffernez C et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by ultrasensitive plasma PCR assay. J Clin Microbiol 2003; 41: 3757-3764.
16. Kaiser L, Perrin L, Chapuis B et al. Improved monitoring of cytomegalovirus infection after allogenic hematopoietic stem cell transplantation by ultrasensitive plasma DNA PCR assay. J Clin Microbiol 2002; 40: 4251-4255.
17. Frome EL, Checkoway H. Use of Poisson regression models in estimating incidence rates and ratios. Am J Epidemiol 1985; 121: 309-323.
18. Haegerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-344.
19. El Amari EB, Toutous-Trellu L, Gayet-Ageron A et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008; 22: 1019-1028.
20. Ledergerber B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999; 282: 2220-2226.
21. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004; 363: 2116-2121.
22. Goossens VJ, Wolffs PF, Van Loo IH, Bruggeman CA, Verbon A. CMV DNA levels and CMV gB subtypes in ART-naïve HAART-treated patients: a 2 year follow-up study in The Netherlands. AIDS 2009; 23: 1425-1429.
23. Tufail A, Moe AA, Miller MJ, Wagar EA, Bruckner DA, Holland GN. Quantitative cytomegalovirus DNA level in the blood and its relationship to cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1999; 106: 133-141.
24. Panagiotakis SH, Soufla G, Baritaki S et al. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients. AIDS Res Hum Retroviruses 2007; 23: 10-18.
25. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Virol 2006; 35: 489-492.
26. Mocarski E Jr. Immunomodulation by cytomegalovirus: manipulative strategies beyond evasion. Trends Microbiol 2002; 10: 332-339.
27. Reinke P, Prösch S, Kern F, Volk HD. Mechanism of cytomegalovirus (re)activation and its impact on organ transplant patients. Transplant Infect Dis 1999; 1: 157-164.
28. Limaye AP, Kirby KA, Rubenfeld GD et al. Cytomegalovirus reactivation in critically immunocompetent patients. JAMA 2008; 300: 413-422.
29. Von Müller L, Klemm A, Durmus N et al. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. JID 2007; 196: 1288-1295.